Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Survodutide in Metabolic Dysfunction Associated Steatohepatitis: NCT06309992 Clinical Landscape Report 2026
15 October 2026
NCT06309992 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Fluciclovine 18F in Glioblastoma, IDH-Wildtype: NCT06319027 Clinical Landscape Report 2026
15 October 2026
NCT06319027 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pegozafermin in Metabolic Dysfunction Associated Steatohepatitis: NCT06318169 Clinical Landscape Report 2026
15 October 2026
NCT06318169 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Plerixafor/Tacrolimus in Amyotrophic Lateral Sclerosis: NCT06315608 Clinical Landscape Report 2026
15 October 2026
NCT06315608 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Recurrent Glioblastoma: NCT06325683 Clinical Landscape Report 2026
15 October 2026
NCT06325683 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VSA-006 in Metabolic Dysfunction Associated Steatohepatitis: NCT06322628 Clinical Landscape Report 2026
15 October 2026
NCT06322628 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
RVP-001 in Von Hippel-Lindau Disease: NCT06322342 Clinical Landscape Report 2026
15 October 2026
NCT06322342 clinical landscape for Von Hippel-Lindau Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atezolizumab in Glioblastoma, IDH-Wildtype: NCT06328036 Clinical Landscape Report 2026
15 October 2026
NCT06328036 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atorvastatin Calcium in Glioblastoma, IDH-Wildtype: NCT06327451 Clinical Landscape Report 2026
15 October 2026
NCT06327451 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lorlatinib in Diffuse midline glioma, point mutation K27M in histone H3: NCT06333899 Clinical Landscape Report 2026
15 October 2026
NCT06333899 clinical landscape for Diffuse midline glioma, point mutation K27M in histone H3: endpoints, sponsor, phase, geography, readouts, asset context a…
9 min read
Sulfur Hexafluoride in Glioblastoma Multiforme: NCT06329570 Clinical Landscape Report 2026
15 October 2026
NCT06329570 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fibromun in Glioblastoma: NCT06336291 Clinical Landscape Report 2026
15 October 2026
NCT06336291 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.